1-3 of 3
Karl S. Peggs
Close
Sort by
Journal Articles

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting

Maria A. V. Marzolini, Varun Mehra, Kirsty J. Thomson, Eleni Tholouli, Adrian J. C. Bloor, Anne Parker, Richard Lovell, Kim Orchard, Amy Publicover, Emma Nicholson, John A. Snowden, Jennifer Byrne, Anjum Khan, Maria H. Gilleece, Gerardo Errico, Sara Lozano, Erin Hurst, Nick Duncan, Jennifer Pirrie, Philip Crea, Ben Carpenter, Antonio Pagliuca, Karl S. Peggs
Journal: Blood Advances
Blood Adv (2021) 5 (21): 4500–4503.
https://doi.org/10.1182/bloodadvances.2021005637
Published: 2021
Journal Articles

Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study

Clinical Trials & Observations
Emma Das-Gupta, Kirsty J. Thomson, Adrian J. C. Bloor, Andrew D. Clark, Stephen Mackinnon, Irfan Kayani, Laura Clifton-Hadley, Pip Patrick, Nadjet El-Mehidi, Anthony Lawrie, Amy A. Kirkwood, Nigel H. Russell, David C. Linch, Karl S. Peggs
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4264–4270.
https://doi.org/10.1182/bloodadvances.2019001016
Published: 2019
Journal Articles

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Karl S. Peggs
Journal: Blood Advances
Blood Adv (2018) 2 (7): 817–820.
https://doi.org/10.1182/bloodadvances.2017011122
Published: 2018